The cluster of C-suite selling at similar prices is a modest bearish signal, but the small percentage of market cap limits material impact. Monitor for any upcoming earnings or corporate events that may have prompted the sales.
CORT drugs
CORT drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 4 $74.89entry
- T+1 · 6mo ago −3.03%α −0.43% · $72.62
- T+5 · 5mo ago +11.16%α +13.72% · $83.25
- T+20 · 4mo ago +20.46%α +21.83% · $90.21
- T+60 · 3mo ago +52.06%α +50.18% · $113.88
Price Chart
How similar events traded
Executive Summary
Four Corcept Therapeutics insiders, including the CEO, CFO, and two other senior executives, sold a total of $5.50M in open-market shares over a one-week window. The sales are concentrated at the C-suite level and represent a material 0.07% of the company's $7.6B market cap. While the dollar amount is modest relative to market cap, the cluster of C-suite selling at similar prices and dates warrants attention, though the sales may be partially explained by option exercises and tax planning.
Key Financial Metrics
Key Facts
- Four insiders sold a total of $5.50M in open-market shares from May 27 to June 1, 2026.
- CEO Joseph Belanoff sold 12,837 shares for $895K at $69.74.
- CFO Atabak Mokari sold 40,000 shares for $2.80M at $70.00.
- Sean Maduck sold 21,069 shares for $1.48M at $70.11.
- Joseph Lyon sold 5,000 shares for $325K at $65.00.
- Total sales represent approximately 0.07% of Corcept's $7.6B market cap.
- All sales occurred near the stock's current price of ~$70, with no significant premium or discount.
- The cluster includes concurrent option exercises and tax-withholding transactions, suggesting some sales may be liquidity-driven.
Financial Impact
Total insider sales of $5.50M, representing 0.07% of market cap.
Risk Factors
- Insider sales may signal management's view that the stock is fairly valued or overvalued near $70.
- The cluster includes option exercises and gifts, which may indicate portfolio diversification rather than a bearish outlook.
- The stock's high analyst bullishness (83% buy ratings) could be contradicted by insider selling.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-CORT-1780529126867 |
Track record
36 reports on CORT
8 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +63.06% at T+60 after the Feb 24, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $73.87 Now $69.22 −6.29% settles Dec 15
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $74.53 Now $69.22 −7.12% settles Dec 10
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $71.63 Now $69.22 −3.36% settles Dec 4
- Nov 3, 202613d ago 8-K Bullish 6/10 Entry $79.22 Now $69.22 −12.62% settles Dec 3
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $81.93 Now $69.22 +15.51% settles Dec 2
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $86.28 Now $69.22 −19.77% settles Nov 25
- Oct 5, 20266w ago Insider Cluster Neutral 3/10 Entry $119.57 to $81.93 Now $69.22 −42.11% ▼ −31.48% −28.30% vs SPY
- Sep 23, 20267w ago 8-K Neutral 3/10 Entry $112.94 to $116.28 Now $69.22 −38.71% ▲ +2.96% +2.27% vs SPY
- Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.50% vs SPY
- Sep 16, 20268w ago Insider Cluster Bearish 4/10 Entry $114.86 to $113.37 Now $69.22 +39.74% ▲ +1.30% +2.75% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers